Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
15.85
-1.07 (-6.32%)
At close: Feb 27, 2026, 4:00 PM EST
15.62
-0.23 (-1.42%)
After-hours: Feb 27, 2026, 7:28 PM EST
Mesoblast Revenue
In the fiscal year ending June 30, 2025, Mesoblast had annual revenue of $17.20M with 191.39% growth. Mesoblast had revenue of $25.67M in the half year ending December 31, 2025, with 1,102.95% growth.
Revenue (ttm)
$17.20M
Revenue Growth
+118.53%
P/S Ratio
31.50
Revenue / Employee
$807,210
Employees
81
Market Cap
2.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 17.20M | 11.30M | 191.39% |
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
| Jun 30, 2019 | 16.72M | -619.00K | -3.57% |
| Jun 30, 2018 | 17.34M | 14.93M | 618.95% |
| Jun 30, 2017 | 2.41M | -40.14M | -94.33% |
| Jun 30, 2016 | 42.55M | 22.79M | 115.31% |
| Jun 30, 2015 | 19.76M | - | - |
| Jun 30, 2013 | - | - | - |
| Jun 30, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Galapagos NV | 1.31B |
| Ultragenyx Pharmaceutical | 673.00M |
| Zai Lab | 441.63M |
| Stoke Therapeutics | 205.63M |
| Ascentage Pharma Group International | 54.52M |
| Ocular Therapeutix | 51.95M |
| Immunome | 9.68M |
| Dianthus Therapeutics | 3.08M |
MESO News
- 2 days ago - Mesoblast (MESO) Reports Significant Miss in 1H Earnings - GuruFocus
- 2 days ago - Mesoblast misses H1 estimates - Seeking Alpha
- 2 days ago - Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Half Year 2026 Mesoblast Ltd Earnings Presentation Transcript - GuruFocus
- 2 days ago - Ryoncil® Profits Underpinning Substantial Growth Pipeline - GlobeNewsWire
- 3 days ago - What's Next: Mesoblast's Earnings Preview - Benzinga
- 9 days ago - Mesoblast Financial Results and Corporate Update Webcast - GlobeNewsWire
- 17 days ago - Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy - Benzinga